anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides a traditional Chinese medicinal preparation for treating aphthous ulcer and a preparation method thereof. The traditional Chinese medicinal preparation of the present invention is made from 50 to 200g of inula cappa, 10 to 40g of licorice, 1 to 4g of pearl, 0.5 to 2g of borneol and a proper quantity of supplementary material. Compared with the prior art, the prescription of the present invention, which is used as an empirical prescription and applied for many years, has a solid clinic basis and reasonable extraction process, prepared dripping pills overcome the defects of easy moisture absorption, inconvenient storage, large daily dose, poor mouth feelings, difficult quality control, bad stability, etc. of a finished product. Compared with congener varieties, the present invention has the characteristics of refined prescription, special efficacy, clear ingredients, safe and effective clinical application, stable and controllable quality, etc. In addition, the preparation is locally taken in the mode of oral taking, medicine directly acting on an ulcer position is absorbed by mucous membranes, and fast therapeutical effect is achieved.
Systemic Safety

The major adverse effects of inhaled beta2-adrenergic agonists occur as a result of excessive activation of systemic beta-adrenergic receptors. The most common adverse effects in adults include skeletal muscle tremor and cramps, insomnia, tachycardia, decreases in serum potassium, and increases in plasma glucose.

Changes in serum potassium were evaluated in COPD patients in double-blind phase 3 studies. In pooled data, at the recommended 5 mcg dose there was no clinically relevant change compared to placebo in serum potassium.

Cardiac Electrophysiology

The effect of STRIVERDI RESPIMAT on the QT/QTc interval of the ECG was investigated in 24 healthy male and female volunteers in a double-blind, randomized, placebo- and active (moxifloxacin)- controlled study at single doses of 10, 20, 30, and 50 mcg. Dose-dependent QTcI (individual subject corrected QT interval) prolongation was observed. The maximum mean (one-sided 95% upper confidence bound) difference in QTcI from placebo after baseline correction was 2.5 (5.6) ms, 6.1 (9.2) ms, 7.5 (10.7) ms and 8.5 (11.6) ms following doses of 10, 20, 30 and 50 mcg, respectively.

The effect of 5 mcg and 10 mcg STRIVERDI RESPIMAT on heart rate and rhythm was assessed using continuous 24-hour ECG recording (Holter monitoring) in a subset of 772 patients in the 48-week, placebo-controlled phase 3 trials. There were no dose- or time-related trends or patterns observed for the magnitudes of mean changes in heart rate or premature beats. Shifts from baseline to the end of treatment in premature beats did not indicate meaningful differences between STRIVERDI RESPIMAT 5 mcg, 10 mcg, and placebo.
Participants enrolled spontaneously breathing preterm infants born between 24 and 29.9 weeks' gestational age with signs of respiratory distress syndrome. The initial respiratory support mode of premature infants assigned to NCPAP group was NCPAP. Patients diagnosed with NRDS on NCPAP were given a therapeutic dose of pulmonary surfactant via MISA within 120 minutes after birth. NCPAP group ventilator parameter setting: PEEP 6cmH2O (adjustment range 6-8cmH2O), FiO2 adjustment range 0.21-0.40, in order to achieve postnatal target oxygen saturation.
The invention concerns a methods for producing lymphocytic cells, as well as tools, reagents and kits useful for implementing same. More particularly, it concerns methods for preparing .gamma..delta. T cells, adapted to industrial production of functional cells of pharmaceutical quality in large amounts. The invention also concerns methods for activating .gamma..delta. T cells, devices adapted to said methods, as well as the resulting cell compositions and their human or animal .gamma..delta. T cells, and can be used in pharmaceutics, therapeutics, experiments, cosmetics, industrial research among others.
People with moderate dementia according to the Clinical Dementia Rating (n = 40). This group will be used to assess the severity of paratonia in the various stages of dementia.
Complications after surgery are common in patients who undergo mastectomies, as in every surgery. Mastectomy patients need to protect the wound area and the arm on the side where a mastectomy is performed following surgery. The process of wound healing and return to the patient's daily life in the post-surgery process parallels. In the early post-operative period, patients have difficulty carrying out daily living activities and need support, while in the late-term they are able to perform daily living activities more independently from caregivers and nurses.

Objective: This research was planned to examine the body value of mastectomy patients, care dependence and psychosocial adaptation-self-knowledge levels of the Web Assisted Interactive Nursing Program (WDIHP) designed according to the Self-Regulation Model.

Method: The research is designed as a mixed-method study of qualitative-quantitative research methods, designed according to the Self-Regulation Model, to examine the effect of WDHP on adaptation to social life, self-efficacy, and body value in patients undergoing breast cancer surgery. This study will use exploratory hybrid methods from mixed research methods. Qualitative interviews will be held face-to-face. Interviews with participants will continue until data saturation is achieved. In the qualitative part of the research, the in-depth interview method will be selected and the "Semi-Structured Interview Form" will be used as a data collection tool. All interviews will be recorded in digital format, returned to writing and then transferred to qualitative analysis software MAXQDA. The quantitative part of the study will be carried out as a randomized controlled trial using the block randomization method. Randomization will be done by a statistician other than the researcher. Power analysis was calculated using G \* Power 3.1.9.7 program. With 0.95 effect size, 95% power and 0.05 significance level, the required sample size was determined as 30 individuals per group, and 60 individuals in total. It was decided to include 67 individuals, 35 individuals in the intervention group and 31 individuals in the control group, by taking 15% more of the calculated sample against the possibility of sample loss during the study. The correct perceptions that may arise as a result of qualitative work will be supported in the relevant sections of the training. In the quantitative section of the research, the interactive web-assisted nurse program will take 1 week and the application will take 3 weeks. A text message will be sent to individuals to their phone to remind them to use the website. Messages will be sent twice a week, a total of 8 times. It will be used as Care Dependency, Body value, psychosocial Compliance to disease, website usability Scale measurement tools. After each assessment, the data obtained will be transferred to the "Social Sciences Software Statistical Package (SPSS).
PURPOSE: A composition containing silicon resin and fluid silicon-based copolymer and liquid volatile linear alkane is provided to generate uniform coating and color. CONSTITUTION: A composition for treating keratin fiber contains silicone resin and fluid silicone-based copolymer, one or more liquid volatile linear alkane of 9-15 carbon atoms. The volatile linear alkane is derived from a plant. The composition contains 0.5-90 weight% of volatile linear alkane based on total weight. The composition is applied to treat keratin fiber and is dried over 40°C after the application. The composition contains pigment.
The present invention relates to nucleic acid molecules having a novel structure which induce RNAi, and to the uses thereof. More particularly, the present invention relates to nucleic acid molecules which have a novel structure and which increase the rate of inhibiting the expression of target genes by configuring the structure to have a first strand of 24-121 nt in length provided with a partial region complementary to a target nucleic acid, and a second strand of 13-21 nt in length provided with a region which forms a complementary bond with the partial region complementary to the target nucleic acid of the first strand. The invention further relates to a method for inhibiting the expression of the target genes using the nucleic acid molecules. The nucleic acid molecular structure according to the present invention can increase a gene inhibition rate, or increase the inhibition rate of the target genes by improving the bonding strength to the same target genes together with siRNA through the introduction of antisense DNA, antisense RNA, ribozyme, and DNAzyme, or by causing synergistic cleavage. Furthermore, the nucleic acid molecules according to the present invention enables the continuance time of a gene inhibition rate to be lengthened. Thus, the nucleic acid molecules inducing RNAi are useful since they replace the conventional siRNA molecules applicable to the treatment of cancer or of viral infection using siRNA.
This multicenter, randomized trial will be conducted with 80 dementia caregivers, who will be randomized into two groups. One group consists of 40 participants who will receive behavioral intervention and 40 who will not receive intervention (waitlist control). The waitlist control group will be also provided the same intervention after the intervention group has completed the intervention. The behavioral intervention consists of 90-min-session a day with an interval of two weeks for 2 months. The intervention program includes not only the knowledge of dementia and how to manage behavioral problems of patients with dementia but also individual psychological counselling about caregiver's distress. The primary outcome measures are the changes in scores of Zaret's Burden Inventory and Philadelphia Geriatric Center for Moral Scale (PGCMS). Secondary outcomes are changes in scores of neuropsychiatric inventory and Korean -instrumental Activities of Daily Living of patients as well as depression scores of caregivers.
Different tasks have been used in examining the neural functional differences associated with developmental dyslexia (DD), and consequently, different findings have been reported. However, very few studies have systematically compared multiple tasks in understanding what specific task differences each brain region is associated with. In this study, we employed an auditory rhyming task, a visual rhyming task, and a visual spelling task, in order to investigate shared and task-specific neural differences in Chinese children with DD. First, we found that children with DD had reduced activation in the opercular part of the left inferior frontal gyrus (IFG) only in the two rhyming tasks, suggesting impaired phonological analysis. Children with DD showed functional differences in the right lingual gyrus/inferior occipital gyrus only in the two visual tasks, suggesting deficiency in their visuo-orthographic processing. Moreover, children with DD showed reduced activation in the left dorsal inferior frontal gyrus and increased activation in the right precentral gyrus across all of the three tasks, suggesting neural signatures of DD in Chinese. In summary, our study successfully separated brain regions associated with differences in orthographic processing, phonological processing, and general lexical processing in DD. It advances our understanding about the neural mechanisms of DD.
Tetrabenazine can cause parkinsonism.  
  
In a 12-week double-blind, placebo-controlled study in patients with chorea associated with HD, symptoms suggestive of parkinsonism (i.e., bradykinesia, hypertonia and rigidity) were observed in 15% of tetrabenazine-treated patients compared to 0% of placebo-treated patients. In 48-week and 80-week, open-label studies, symptoms suggestive of parkinsonism were observed in 10% and 3% of tetrabenazine-treated patients, respectively.   
Because rigidity can develop as part of the underlying disease process in Huntington’s disease, it may be difficult to distinguish between this drug-induced adverse reaction and progression of the underlying disease process. Drug-induced parkinsonism has the potential to cause more functional disability than untreated chorea for some patients with Huntington’s disease. If a patient develops parkinsonism during treatment with tetrabenazine tablets, dose reduction should be considered; in some patients, discontinuation of therapy may be necessary.
Randomization of a total of approx. 200 subjects to one of four treatment arms at 1:1:1:1 ratio to receive 1.25 µg of the RRV Vaccine with/without adjuvant (Al(OH)3), or 2.5 µg of the RRV Vaccine with/without adjuvant (Al(OH)3). Cohort 1 is subdivided into Cohort 1a (n = 60, i.e. 15 subjects per dose/adjuvantation combination) to receive the first vaccination on Day 0, with Day 7 safety data being reviewed by a Data Monitoring Committee and, following DMC recommendation, to receive the second vaccination at Day 21; Cohort 1b (n=140, i.e. 35 subjects per dose/adjuvantation combination) is to be vaccinated twice 21 days apart upon availability of DMC recommendation. Booster vaccination to follow 180 days after first vaccination.
Stabilisation of the infant is performed while the cord is intact and the cord will be clamped after the infant is cardiopulmonary stable. Stable is defined as the establishment of heart rate greater than 100 bpm and oxygen saturation above 85% while using supplemental oxygen lower than 40%. The maximum cord clamping time is 10 minutes and prior to cord clamping a trial of weaning from PPV to CPAP is performed. With the exception that the infant is stabilised close to the mother and the cord is clamped later, the infant will receive standard resuscitation interventions.
Sweat is a watery solution containing trace amounts of proteins and peptides that may contribute to the antimicrobial defense system of the skin barrier, playing a role in innate immune responses against potential pathogens. The peptide and metabolite composition of sweat has not been fully explored. Evidence suggests that the composition of the skin barrier could vary with diseases. The causes and consequences of the changes of sweat proteins and peptides in humans are unknown. This clinical trial will focus on multiomics analysis of sweat, mainly of the antimicrobial peptides that play a key role in the host-pathogen interaction. Antioxidants, anti-bacterial and anti-inflammatory compounds may contribute to the regulation of systemic inflammation and pathophysiological disorders. In cystic fibrosis, inflammatory responses are altered, exaggerated and persistent, even in the absence of infection. It is therefore relevant to study the influence of CFTR mutations on the profile of antimicrobial peptides expressed in sweat. The clinical study will potentially lead to the discovery of novel non-invasive biomarkers of the disease in sweat.
Many women report postpartum perineal pain due to perineal trauma after vaginal delivery. Perineal pain after giving birth declines over time; however, perineal trauma and pain negatively impact on the women's quality of life and their ability to care for their children. The degree of perineal trauma and instrument delivery with episiotomy are associated with perineal pain. Nevertheless, no studies have examined factors related to postpartum perineal pain, including weight changes during pregnancy as well as the course of delivery so far. We aimed to elucidate obstetric factors associated with perineal pain after vaginal delivery on the first postnatal day in Japanese primiparous women. A cross-sectional study conducted in five maternity hospitals in Japan included 142 primiparous women who vaginally delivered full-term and singleton infants. Perineal pain on the first postnatal day was evaluated using a visual analog scale. The final analysis included 92 participants with a mean age of 30.3 ± 4.6 years. The median visual analog scale score was 54.0 mm. Multiple linear regression analysis demonstrated that gestational weight gain above the recommended Japanese range was positively and significantly associated with perineal pain on the first postnatal day, independent of maternal age, episiotomy, painkiller use, and neonatal birth weight. This finding may provide additional evidence regarding gestational weight gain within the recommended range based on the pre-pregnancy body mass index to reduce perineal pain on the first postnatal day.
Method to obtain neural stem cells and neural progenitor cells from non-embryonic ovarian cortical tissue. The present invention relates to a method for obtaining neural stem cells and neural progenitor cells (ctn/cpn) from ovarian cortical tissue of mammalian prepubertal females, without the need to add induction and/or expansion factors to the culture medium. Neural lineage. With the method of the invention ctn/cpn are obtained after 6-21 days of incubation, improving the results by adding fsh to the culture medium. The ctn/cpn obtained by this method can be used in experimental models of in vitro neurogenesis, in targeted differentiation of ctn/cpn to generate various types of nerve cells of interest in regenerative medicine of the nervous system, with application to autologous transplantation in cellular therapy of neurodegenerative pathologies, as well as for the evaluation of neurotoxicity of various drugs, contaminants and chemical compounds. (Machine-translation by Google Translate, not legally binding)
PROBLEM TO BE SOLVED: To provide a sustained release microcapsule which comprises a core substance enclosed in a porous polymer shell film having strengths enough to protect the core substance by specifying the average thickness and average micropore size of the polymer shell film. SOLUTION: The shell film enclosing the core substance, e.g. an ester, comprises an org, polymer substance, e.g. a polyamide, and has an average thickness of 1-80 μm, pref. 5-50 μm, and an average micropore size of 1-100 μm, pref. 2-80 μm. Thus, the capsule strength is high enough and the core substance can be slowly released over a long time without leaking. The thickness of the shell film can be adjusted by adjusting the amts. of oil-soluble and water- soluble monomers reactive with the film. The micropore size can be controlled, e.g. by adjusting the method for adding a reaction accelerator in forming a polyamide film.
BACKGROUND: Alzheimer's disease (AD) is considered to have a multifactorial etiology. The hallmark of AD is progressive neurodegeneration, which is characterized by the deepening loss of memory and a high mortality rate in the elderly. The neurodegeneration in AD is believed to be exacerbated following the intercoupled cascades of extracellular amyloid beta (Aβ) plaques, uncontrolled microglial activation, and neuroinflammation. Current therapies for AD are mostly designed to target the symptoms, with limited ability to address the mechanistic triggers for the disease. In this study, we report a novel nanotechnology based on microglial scavenger receptor (SR)-targeting amphiphilic nanoparticles (NPs) for the convergent alleviation of fibril Aβ (fAβ) burden, microglial modulation, and neuroprotection.
METHODS: We designed a nanotechnology approach to regulate the SR-mediated intracellular fAβ trafficking within microglia. We synthesized SR-targeting sugar-based amphiphilic macromolecules (AM) and used them as a bioactive shell to fabricate serum-stable AM-NPs via flash nanoprecipitation. Using electron microscopy, in vitro approaches, ELISA, and confocal microscopy, we investigated the effect of AM-NPs on Aβ fibrilization, fAβ-mediated microglial inflammation, and neurotoxicity in BV2 microglia and SH-SY5Y neuroblastoma cell lines.
RESULTS: AM-NPs interrupted Aβ fibrilization, attenuated fAβ microglial internalization via targeting the fAβ-specific SRs, arrested the fAβ-mediated microglial activation and pro-inflammatory response, and accelerated lysosomal degradation of intracellular fAβ. Moreover, AM-NPs counteracted the microglial-mediated neurotoxicity after exposure to fAβ.
CONCLUSIONS: The AM-NP nanotechnology presents a multifactorial strategy to target pathological Aβ aggregation and arrest the fAβ-mediated pathological progression in microglia and neurons.
A medical records software apparatus and method is described that allows a clinician, e.g., nurse or doctor, to combine entry of new patient orders, prescriptions, flowsheet observations, etc. into the documentation process or workflow. A documentation user interface is provided that pulls patient data from a database into the display. The user can select on the user interface a category of a patient record, e.g., Significant Events or Orders, view or edit prior entries in the database in these categories, and add additional documentation for that category. The documentation is written or pushed to two areas of the database, one devoted to patient documentation and a second area corresponding to the selected category, e.g., Orders. The method and apparatus improves workflow efficiency and promotes a smooth transition from the thought process of the clinician to the ordering or prescription process, without the need for changing venues or screen displays to both enter documentation and enter the order or new prescription.
The participants in this arm will be prescribed an aerobic and strengthening exercise program often prescribed to those with knee OA. The program will include 15 minutes of walking per class, closed kinetic chain strengthening exercises on machines, and a cool down consisting of stretching. Participants will be asked to come to class 3 times per week for 12 weeks. Certified Kinesiologists as well as student volunteers will be available during all class times for program completion and progression.
PROBLEM TO BE SOLVED: To extract and refine a high yield of a viscous polysaccharide keeping its natural structure in a plant body by extracting the viscous polysaccharide from a plant of the Malvales with water, filtering the extract and depositing the viscous polysaccharide from the filtrate. SOLUTION: At least one plant body selected from a fruit, a seed, a leaf, a root, a stalk and a flower of a plant of the Malvales is turned into an extractable shape by crushing or the like. A viscous polysaccharide is extracted from it with water 1-10 times as much in weight at 0-15 deg.C for 3-24 hr. By filtering the extract, a filtrate containing the viscous polysaccharide is separated from a residue. A fibrous viscous polysaccharide is deposited by adding an alcohol or the like 0.2-10 times as much in weight as the filtrate into the filtrate which is stirred mildly. By filtering out the deposit and optionally drying it at 20-60 deg.C, a viscous polysaccharide having a structure with the basic skeleton of saccharides containing galacturonic acid, glucuronic acid, rhamnose, galactose and glucose and acetylated saccharides of them is obtained. This process is executable in an industrial scale for the preparation of a viscous polysaccharide to be used safely as a food and a food additive.